September 22, 2009
All three components of sexual health -- desire, function, and satisfaction -- may be negatively impacted for men taking standard therapy for chronic hepatitis C, new research shows.
"Men planning to receive peginterferon and ribavirin should be counseled about the possibility of a decline in sexual health during treatment and receive adequate support if these side effects occur," according to lead author Dr. Lorna M. Dove of New York Presbyterian Medical Center and colleagues.
The subjects of the current study were 260 men taking the combination treatment for chronic hepatitis C. They completed self-administered questionnaires before, during, and after treatment.
When therapy ended, at 24 or 48 weeks, 38-48 percent of the men said their "overall sexual function was worse than before treatment." Caucasian-American men reported more impairment than African-American men.
"By 24 weeks after treatment, sexual desire and satisfaction improved and were comparable to baseline levels," the authors wrote. "However, among men who received 48 weeks of therapy, the estimated percentage of men reporting post-treatment erectile or ejaculatory problems remained higher than baseline, although persistent erectile impairment was limited to Caucasian-American patients."
"Sexual impairment is common among men with chronic hepatitis C undergoing therapy with pegylated interferon and ribarvirin and should be considered as a potential side effect of antiviral therapy," the authors concluded.
The report, "Decline in Male Sexual Desire, Function and Satisfaction During and After Antiviral Therapy for Chronic Hepatitis C," was published in Gastroenterology (2009;137(3):873-884).
09.16.09; Reuters Health
|Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds|
|Which HIV Treatment Regimens Are Recommended for Newly Diagnosed Patients?|
|Weekly PRO 140 Antibody Injections May Work as HIV Maintenance Therapy|
|This Week in HIV Research: Effects of Treatment on Arterial Inflammation; Mortality Rate After 5 Years of Treatment Not Impacted by Initial CD4 Count|
|Investigational Integrase Inhibitor Bictegravir Safe and Effective Against HIV in Early Study|